Trex Wind-down, Inc.

Equities

TMBRQ

US8870802084

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:22:21 2024-04-24 am EDT			5-day change	1st Jan Change
0.0002 ^USD	0.00%		0.00%	-83.33%

Apr. 04	First Motion for Exclusivity Period Extension Approved For Timber Pharmaceuticals, Inc.	CI
Mar. 20	Second Revised Disclosure Statement and Plan Approved on Interim Basis for Timber Pharmaceuticals, Inc.	CI

Notice for Auction Cancellation Filed by Timber Pharmaceuticals, Inc.

January 04, 2024 at 11:00 pm EST

Timber Pharmaceuticals, Inc. filed a notice for the termination of the auction for the sale of substantially all its assets on January 5, 2024. The auction was scheduled for January 4, 2024. The debtor did not received any qualified bids other than the stalking horse bid.

Latest news about Trex Wind-down, Inc.

First Motion for Exclusivity Period Extension Approved For Timber Pharmaceuticals, Inc.	Apr. 04	CI
Second Revised Disclosure Statement and Plan Approved on Interim Basis for Timber Pharmaceuticals, Inc.	Mar. 20	CI
First Motion for Exclusivity Period Extension Filed by Timber Pharmaceuticals, Inc.	Mar. 15	CI
Timber Pharmaceuticals, Inc. Presents Preliminary Results from the ASCEND Trial in A Late-Breaking Session At the 2024 American Academy of Dermatology Annual Meeting	Mar. 10	CI
Combined Joint Liquidation Plan & Disclosure Statement Filed by Timber Pharmaceuticals, Inc.	Feb. 27	CI
Motion for Asset Sale Approved for Timber Pharmaceuticals, Inc.	Jan. 21	CI
LEO Pharma A/S completed the acquisition of Substantially All the assets from Timber Pharmaceuticals, Inc. (OTCPK:TMBR.Q).	Jan. 21	CI
Notice of Selection of Winning Bidder & Asset Purchase Agreement Filed for Timber Pharmaceuticals, Inc.	Jan. 04	CI
Notice for Auction Cancellation Filed by Timber Pharmaceuticals, Inc.	Jan. 04	CI
Bidding Procedure Approved for Timber Pharmaceuticals, Inc.	Dec. 14	CI
Final DIP Financing Approved for Timber Pharmaceuticals, Inc.	Dec. 14	CI
Timber Pharmaceuticals to Be Delisted From NYSE American	Nov. 29	MT
Timber Pharmaceuticals Receives Court Approval of Motions to Support Business Operations	Nov. 29	MT
Timber Pharmaceuticals, Inc.(NYSEAM:TMBR) dropped from S&P TMI Index	Nov. 24	CI
Interim DIP Financing Approved for Timber Pharmaceuticals, Inc.	Nov. 21	CI
Motion for Joint Administration Approved for Timber Pharmaceuticals, Inc.	Nov. 21	CI
Motion for Joint Administration Filed by Timber Pharmaceuticals, Inc.	Nov. 18	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Nov. 17	MT
Sector Update: Health Care	Nov. 17	MT
Timber Pharmaceuticals Fails to Get Shareholder Approval For Merger	Nov. 17	MT
Timber Pharmaceuticals Trading Halted, Pending Material News Release	Nov. 17	MT
Timber Pharmaceuticals, Inc. Filed for Bankruptcy	Nov. 17	CI
Motion for Asset Sale Filed by Timber Pharmaceuticals, Inc.	Nov. 16	CI
LEO Pharma A/S entered into stalking horse asset purchase agreement to acquire Substantially All the assets from Timber Pharmaceuticals, Inc. (OTCPK:TMBR.Q) for $14.35 million.	Nov. 16	CI
LEO Pharma A/S cancelled the acquisition of Timber Pharmaceuticals, Inc..	Nov. 16	CI

Chart Trex Wind-down, Inc.

Duration

Period

More charts

Company Profile

Trex Wind-Down, Inc., formerly Timber Pharmaceuticals, Inc., has filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code and is winding down its business. The Company has no operation nor generates any revenue.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TREX WIND-DOWN, INC.	-83.33%	617
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research